Naval Medical Center, San Diego, California, USA.
Dermatol Surg. 2010 Apr;36(4):470-4. doi: 10.1111/j.1524-4725.2010.01475.x. Epub 2010 Feb 17.
The alexandrite laser selectively targets melanin and hemoglobin. We used the alexandrite laser with variable pulse widths to treat facial telangiectasia.
Nineteen patients were enrolled in this study, which consisted of two parts: a series of test spots over a range of pulse durations (3-80 ms) and treatment over a larger area based on the pulse width-specific outcomes from the test spots. The final follow-up visit was 12 weeks after irradiation.
The 40-ms pulse width achieved the optimal balance of pain tolerance, epidermal tolerance, and vessel reduction. Mean fluence was 88 J/cm(2), with a 6-mm spot. Overall, a 48% reduction in vessels was noted after one treatment. Side effects were minimal.
In fair-skinned patients with large telangiectasia, the alexandrite laser is a good option for vessel reduction.
亚历山大激光选择性地靶向黑色素和血红蛋白。我们使用可变脉宽的亚历山大激光治疗面部毛细血管扩张症。
本研究纳入了 19 名患者,包括两个部分:一系列测试点,涵盖了不同的脉冲持续时间(3-80 毫秒),以及根据测试点的脉冲宽度特异性结果对更大面积进行治疗。最后一次随访是在照射后 12 周。
40 毫秒的脉冲宽度实现了疼痛耐受、表皮耐受和血管减少之间的最佳平衡。平均能量密度为 88J/cm(2),光斑大小为 6mm。总体而言,单次治疗后血管减少了 48%。副作用极小。
对于皮肤白皙、毛细血管扩张较大的患者,亚历山大激光是减少血管的一种较好选择。